Welcome to our dedicated page for Biolinerx news (Ticker: BLRX), a resource for investors and traders seeking the latest updates and insights on Biolinerx stock.
BioLineRx Ltd. develops oncology and rare-disease therapies, with recurring updates centered on GLIX1, APHEXDA (motixafortide), and motixafortide development in solid tumors.
Company news covers GLIX1 clinical development for glioblastoma and other solid tumors under its Hemispherian collaboration, intellectual-property developments tied to GLIX1, financial results, and corporate updates. APHEXDA is approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma and is commercialized by partners, while BioLineRx has retained motixafortide rights for solid-tumor programs including metastatic pancreatic cancer.
BioLineRx (NASDAQ: BLRX) reported unaudited Q1 2026 results and key oncology updates. Revenue was $0.5 million, mainly APHEXDA royalties, with APHEXDA Q1 sales of $2.7 million. Net loss was $2.6 million versus prior-year net income of $5.1 million, and cash/bank deposits totaled $17.4 million, supporting cash runway into H1 2027.
The first patient was dosed in the Phase 1/2a GLIX1 glioblastoma trial, with additional centers participating, and new preclinical GBM data showed potent anti-tumor effects, including in temozolomide-resistant models. Enrollment continues in the motixafortide Phase 2b mPDAC trial.
BioLineRx (NASDAQ: BLRX) and Hemispherian announced two ASCO 2026 abstracts on GLIX1, a first-in-class oral small molecule that restores TET2 activity and targets the DNA damage response.
Preclinical data show brain-penetrant antitumor activity in glioblastoma models, favorable animal safety, and synergistic cytotoxicity when combined with multiple PARP inhibitors. A first-in-human Phase 1/2a GBM trial (NCT07464925) is enrolling.
BioLineRx (NASDAQ: BLRX) will report unaudited Q1 2026 results on May 27, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT with CEO Philip Serlin, accessible via phone, live webcast, and replay.
BioLineRx (NASDAQ: BLRX) and Hemispherian reported new preclinical data on GLIX1 in glioblastoma (GBM). Orally administered GLIX1 showed dose-dependent anti-tumor activity in three orthotopic cell-derived xenograft models, with tumor growth inhibition and survival benefit across all doses.
In a new subcutaneous temozolomide (TMZ)-resistant patient-derived xenograft model, GLIX1 produced a robust anti-tumor effect while TMZ showed no effect, supporting the ongoing Phase 1/2a trial in recurrent and progressive GBM and other high-grade gliomas.
BioLineRx (NASDAQ: BLRX) and Hemispherian announced dosing of the first patient in a first-in-human Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
The oral small molecule is designed to restore TET2 activity, induce tumor-selective DNA damage, showed blood-brain-barrier penetration in preclinical models, and will enroll up to 30 patients in Phase 1. Phase 1 data are anticipated in H1 2027.
Hemispherian (BLRX) initiated a first-in-human Phase 1/2a trial of GLIX1 for recurrent and progressive glioblastoma and other high-grade gliomas (NCT07464925) on April 8, 2026. GLIX1 is an oral, first-in-class TET2 activator with reported preclinical anti-tumor activity, brain penetration, and favorable toxicology.
The Phase 1 will enroll up to 30 patients to determine MTD/recommended dose with PK/PD and preliminary efficacy; initial data are anticipated in H1 2027. Multi-center sites include NYU Langone, Northwestern, and Moffitt Cancer Center.
BioLineRx (NASDAQ: BLRX) initiated a first-in-human Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas on March 26, 2026. GLIX1 is an oral TET2 activator with preclinical anti-tumor activity, blood-brain-barrier penetration and favorable toxicology.
The Phase 1 cohort will recruit up to 30 patients to establish MTD/recommended dose; initial Phase 1 data are anticipated in H1 2027. Three academic centers (NYU Langone, Northwestern, Moffitt) will participate.
BioLineRx (NASDAQ: BLRX) reported audited 2025 results and corporate updates on March 23, 2026. Key highlights: $20.9 million cash on hand supporting a runway into H1 2027; net loss $2.0 million in 2025 versus $9.2 million in 2024; USPTO Notice of Allowance for a GLIX1 patent extending protection to 2040 (plus possible extension).
The company expects to initiate a Phase 1/2a GLIX1 glioblastoma trial by month-end, with Phase 1 data targeted in H1 2027; motixafortide interim analysis in mPDAC is anticipated in 2026.
BioLineRx (NASDAQ: BLRX) will release audited financial results for the year ended December 31, 2025 on March 23, 2026 before U.S. markets open. Management will host a conference call on the same day at 8:30 a.m. EDT with CEO Philip Serlin.
Investors can join via dial-in (+1-888-281-1167 U.S.; +972-3-918-0685 international) or via a live webcast on the company website. A webcast replay will be posted about two hours after the call; a dial-in replay is available through March 25, 2026.
BioLineRx (NASDAQ: BLRX) reported Q3 2025 results and a corporate update on November 24, 2025. The company formed a joint venture with Hemispherian to advance GLIX1, a Phase 1-ready oral DDR-targeting small molecule for glioblastoma, with a Phase 1/2a trial expected in Q1 2026. The USPTO issued a Notice of Allowance for a key GLIX1 patent extending protection potentially to 2040 plus up to five years. Cash totaled $25.2M at September 30, 2025, providing runway into H1 2027. Q3 revenue was $0.4M, net loss $1.0M, and APHEXDA royalties were $0.4M.